Theralink Technologies, Inc. is a precision medicine company, which engages in the development of novel cancer immunotherapy products. It offers the reverse phase protein array technology platform that can quantify protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. The company was founded on March 18, 2005 and is headquartered in Golden, CO.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company